KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Assets Average (2016 - 2026)

Pacira BioSciences has reported Assets Average over the past 16 years, most recently at $1.2 billion for Q1 2026.

  • For Q1 2026, Assets Average fell 21.23% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, down 21.23%, while the annual FY2025 figure was $1.4 billion, 9.89% down from the prior year.
  • Assets Average for Q1 2026 was $1.2 billion at Pacira BioSciences, down from $1.3 billion in the prior quarter.
  • Over five years, Assets Average peaked at $2.0 billion in Q1 2022 and troughed at $1.2 billion in Q1 2026.
  • A 5-year average of $1.6 billion and a median of $1.6 billion in 2025 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: surged 54.83% in 2022 and later dropped 21.23% in 2026.
  • Year by year, Assets Average stood at $1.7 billion in 2022, then dropped by 8.98% to $1.6 billion in 2023, then fell by 1.08% to $1.5 billion in 2024, then fell by 16.67% to $1.3 billion in 2025, then decreased by 3.47% to $1.2 billion in 2026.
  • Business Quant data shows Assets Average for PCRX at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.